PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS
Processes and compositions for liposomal delivery of therapeuticals prepared by contacting an aqueous solution of an active agent with a solution of liposome-forming components containing one or more DILA2 amino acid compounds or lipids in organic solvent to form an impinging stream. A protocol including flow rates, pH, and an incubation period are used to control formation of liposomal components for therapeutic applications. The impinging stream may be collected and incubated to prepare a liposomal formulation which encapsulates the active agent. The composition can be quenched with buffer and filtered by tangential flow and diafiltration and other means for finishing as a pharmaceutical composition.
1 . A process for making a composition comprising an active agent, the process comprising:
a) providing a first stream comprising an aqueous buffer solution of an active agent;
b) providing a second stream comprising a non-aqueous solution of one or more liposome-forming compounds in organic solvent;
c) impinging the first stream on the second stream, thereby forming an impinging stream having a concentration of the organic solvent of from about 20% to about 50% v/v, and having a pH of from about 6 to about 7.4;
d) incubating the impinging stream in a collection reservoir for a period of from about 0.5 hours to about 8 hours at a temperature of from about 20° C. to about 35° C., thereby forming an incubate comprising liposomes.
2 . The process of claim 1 , further comprising quenching the incubate by adding buffer to the incubate sufficient to make the concentration of the organic solvent less than about 20% v/v.
3 . The process of claim 1 , wherein the liposome-forming compounds are one or more DILA2 amino acid compounds.
4 . The process of claim 1 , wherein one of the liposome-forming compounds is PONA, C18:1-norArg-C16.
5 . The process of claim 1 , further comprising the volume flow rate of the first stream being five times or more the volume flow rate of the second stream.
6 . The process of claim 1 , further comprising adjusting the pH of the impinging stream to be from about 3 to about 6.
7 . The process of claim 1 , further comprising incubating at a pH from about 3 to about 6.
8 . The process of claim 1 , further comprising adding buffer to the collection reservoir to adjust the concentration of the organic solvent.
9 . The process of claim 1 , further comprising that the active agent is encapsulated in liposomes at a level greater than about 70%.
10 . The process of claim 1 , wherein the active agent is a gene-silencing agent, a gene-regulating agent, an antisense agent, a peptide nucleic acid agent, a ribozyme agent, an RNA agent, or a DNA agent.
11 . The process of claim 1 , wherein the active agent is a UsiRNA.
12 . The process of claim 1 , wherein after tangential flow filtration the liposomes are of uniform size with an average diameter from about 40 nm to about 160 nm.
13 . The process of claim 1 , further comprising adding organic solvent to the first stream at a concentration of from about 1% to about 40% v/v.
14 . The process of claim 1 , wherein the organic solvent is a (C1-6)alkanol at a concentration of about 40 to about 99% v/v in sterile water for injection.
15 . The process of claim 1 , wherein the incubating period is from about 1 hours to about 4 hours.
16 . A pharmaceutical composition made by the process of claim 1 .
17 . A method for inhibiting expression of a gene in a mammal comprising preparing a composition according to claim 16 and administering the composition to the mammal.
18 . A method for treating a disease in a human comprising preparing a composition according to claim 16 and administering the composition to the human, wherein the disease is selected from cancer, bladder cancer, liver cancer, liver disease, hypercholesterolemia, an inflammatory disease, a metabolic disease, inflammation, arthritis, rheumatoid arthritis, encephalitis, bone fracture, heart disease, and viral disease.